We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-14.15%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.67B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
2.74%
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$87.4M
2
BLU
BELLUS Health Inc.
BLU
+$67.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$59.2M
4
RLMD icon
Relmada Therapeutics
RLMD
+$44.5M
5
XLO icon
Xilio Therapeutics
XLO
+$34.1M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$190M
2
TGTX icon
TG Therapeutics
TGTX
+$49M
3
VERV
Verve Therapeutics
VERV
+$23.9M
4
CTMX icon
CytomX Therapeutics
CTMX
+$17.8M
5
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Financials 0.78%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
26
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$63.7M 1.12%
3,593,052
– –
PHAT icon
27
Phathom Pharmaceuticals
PHAT
$660M
$61.3M 1.08%
3,115,008
– –
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$55.9M 0.99%
+381,046
New +$59.2M
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
$54.2M 0.96%
3,333,700
– –
PRDS
30
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$51.2M 0.9%
3,127,038
+2,127,038
+213% +$24.7M
HOWL icon
31
Werewolf Therapeutics
HOWL
$47.6M
$51.1M 0.9%
4,291,881
– –
PNT
32
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$50.4M 0.89%
9,003,018
+147,000
+2% +$1.1M
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$6.66B
$48.6M 0.86%
4,871,067
– –
LIAN
34
DELISTED
LianBio American Depositary Shares
LIAN
$47.2M 0.83%
+7,655,015
New +$87.4M
DSGN icon
35
Design Therapeutics
DSGN
$765M
$46.8M 0.83%
2,186,636
– –
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$374M
$46M 0.81%
2,107,149
– –
RLMD icon
37
Relmada Therapeutics
RLMD
$474M
$45.1M 0.79%
+2,000,000
New +$44.5M
CCCC icon
38
C4 Therapeutics
CCCC
$422M
$44.4M 0.78%
1,377,569
– –
TGTX icon
39
TG Therapeutics
TGTX
$8.12B
$42M 0.74%
2,210,145
-1,888,187
-46% -$49M
EYPT icon
40
EyePoint Inc
EYPT
$316M
$41.3M 0.73%
3,370,506
+1,160,000
+52% +$15.6M
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$40.3M 0.71%
3,577,094
– –
EWTX icon
42
Edgewise Therapeutics
EWTX
$4.74B
$39.9M 0.7%
2,613,623
– –
PMVP icon
43
PMV Pharmaceuticals
PMVP
$72.7M
$39.5M 0.7%
1,710,265
– –
CYT
44
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$38.1M 0.67%
3,350,506
– –
GERN icon
45
Geron
GERN
$842M
$36.8M 0.65%
30,126,299
– –
IVVD icon
46
Invivyd
IVVD
$245M
$36.3M 0.64%
4,995,807
-344,323
-6% -$8.95M
CNTB
47
Connect Biopharma Holdings
CNTB
$73.7M
$36M 0.63%
6,991,003
– –
RXST icon
48
RxSight
RXST
$234M
$34.3M 0.61%
3,052,796
– –
VRNA
49
DELISTED
Verona Pharma
VRNA
$34.3M 0.6%
5,100,000
– –
LENZ
50
LENZ Therapeutics
LENZ
$133M
$33.5M 0.59%
385,481
– –
1
2
3 4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, RA Capital Management held 105 positions worth $5.67B, down 21% from $7.22B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management's Q4 2021 filing shows 10 new, 9 increased, 7 reduced and 8 closed positions. Its largest new stake was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M. The largest sale was Atea Pharmaceuticals, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q4 2021 buy was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $26.8M increase.
  • RA Capital Management's biggest Q4 2021 reduction was TG Therapeutics, cutting an estimated $49M.
  • RA Capital Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $190M.
  • RA Capital Management's ten largest holdings make up 45% of its $5.67B portfolio in Q4 2021.
  • RA Capital Management opened 10 new positions and closed 8 in Q4 2021.
  • RA Capital Management's portfolio value fell 21% quarter-over-quarter to $5.67B.

Based on RA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.